醫(yī)藥行業(yè)并購重組估值的研究
[Abstract]:M & A is an indispensable part of economic operation at present. The valuation of M & A in pharmaceutical industry is an important work for both sides of M & A and intermediary organizations. In the work of M & A, we should not only consider the simplicity of the mode of M & A and reorganization, but also pay attention to avoiding the risks in M & A. The valuation of M & A in pharmaceutical industry should not only consider the commonness with general industry, but also consider the characteristics of pharmaceutical industry. The M & A mode of pharmaceutical industry is divided into high risk project and low risk project according to the size of tax management risk of M & A project. For high-risk projects, the "new shell for the old shell" method is adopted, that is, the original shareholders to establish a new company, the new company to acquire the assets of the original company, after that, the new shareholders to buy the new company's equity restructuring; In view of the M & A project with low risk of tax management, the M & A project can be valued by the market value method, that is, according to the secondary market performance of the listed company (or referring to the comparable listing of the same kind), the price / earnings ratio or the price-to-book ratio is used to evaluate the M & A project. In the process of valuation, we should pay more attention to due diligence, audit and evaluation. In due diligence, full attention should be paid to such items as divestiture, scope of effective assets, unification of accounting policies, and so on. In the audit, sufficient attention should be paid to the integrity of the rebate fee, the authenticity of the rebate income, and the existence of contingent liabilities, etc. In the evaluation work, we should focus on the situation that fair value is higher than the market value, the continuity of preferential tax policy, the selection of discount rate and other key issues.
【學(xué)位授予單位】:首都經(jīng)濟貿(mào)易大學(xué)
【學(xué)位級別】:碩士
【學(xué)位授予年份】:2013
【分類號】:F275;F271;F426.72
【參考文獻(xiàn)】
相關(guān)期刊論文 前10條
1 李淑連;;會計電算化條件下審計中存在的主要問題及對策[J];遼寧科技學(xué)院學(xué)報;2008年04期
2 張雪梅;;審計學(xué)啟發(fā)式研究性教學(xué)方法的創(chuàng)新[J];財會月刊;2007年29期
3 胡南薇;曹強;;中國審計市場是否需要行業(yè)專門化——新審計準(zhǔn)則頒布后的思考[J];財經(jīng)理論與實踐;2008年01期
4 吳可夫;;論公允價值會計的過渡性[J];財經(jīng)理論與實踐;2008年05期
5 蔡春;鮮文鐸;;會計師事務(wù)所行業(yè)專長與審計質(zhì)量相關(guān)性的檢驗——來自中國上市公司審計市場的經(jīng)驗證據(jù)[J];會計研究;2007年06期
6 欒甫貴;;論新會計準(zhǔn)則中的財務(wù)理念[J];會計研究;2008年02期
7 葛家澍;;關(guān)于公允價值會計的研究——面向財務(wù)會計的本質(zhì)特征[J];會計研究;2009年05期
8 黃世忠;;公允價值會計的順周期效應(yīng)及其應(yīng)對策略[J];會計研究;2009年11期
9 葛家澍;竇家春;陳朝琳;;財務(wù)會計計量模式的必然選擇:雙重計量[J];會計研究;2010年02期
10 曹宇波;李小琴;;基于B-S模型的創(chuàng)業(yè)板公司估值模型及其Excel實現(xiàn)[J];會計之友;2011年06期
相關(guān)碩士學(xué)位論文 前9條
1 侯嘉庚;并購中目標(biāo)公司定價實證分析[D];山西財經(jīng)大學(xué);2011年
2 黃科;山德士制藥有限公司(SANDOZ)競爭戰(zhàn)略研究[D];中南大學(xué);2011年
3 李野;太極集團(tuán)戰(zhàn)略研究[D];西南財經(jīng)大學(xué);2007年
4 張正山;黔西南州天地藥業(yè)公司競爭戰(zhàn)略研究[D];貴州大學(xué);2008年
5 關(guān)雪峰;貴州益佰OTC市場營銷策略研究[D];哈爾濱工程大學(xué);2008年
6 何清;公司出資證明責(zé)任研究[D];湖南大學(xué);2008年
7 王新麗;國有企業(yè)并購中的資產(chǎn)評估問題研究[D];北京交通大學(xué);2009年
8 梁珉珉;《琿春鄉(xiāng)土志》之研究[D];延邊大學(xué);2012年
9 劉慧穎;我國農(nóng)村扶貧開發(fā)中的問題及對策研究[D];大連交通大學(xué);2012年
本文編號:2342498
本文鏈接:http://sikaile.net/guanlilunwen/shengchanguanlilunwen/2342498.html